vs
Side-by-side financial comparison of Mega Matrix Inc (MPU) and Prelude Therapeutics Inc (PRLD). Click either name above to swap in a different company.
Prelude Therapeutics Inc is the larger business by last-quarter revenue ($6.5M vs $6.1M, roughly 1.1× Mega Matrix Inc). Mega Matrix Inc runs the higher net margin — -177.4% vs -303.5%, a 126.0% gap on every dollar of revenue. On growth, Prelude Therapeutics Inc posted the faster year-over-year revenue change (116.7% vs -40.9%).
MPU vs PRLD — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.1M | $6.5M |
| Net Profit | $-10.8M | $-19.7M |
| Gross Margin | 47.7% | — |
| Operating Margin | -156.3% | -314.1% |
| Net Margin | -177.4% | -303.5% |
| Revenue YoY | -40.9% | 116.7% |
| Net Profit YoY | -291.1% | 38.9% |
| EPS (diluted) | $-0.21 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $6.1M | $6.5M | ||
| Q2 25 | $7.1M | — | ||
| Q1 25 | $7.7M | — | ||
| Q3 24 | $10.3M | $3.0M |
| Q3 25 | $-10.8M | $-19.7M | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-2.5M | — | ||
| Q3 24 | $-2.8M | $-32.3M |
| Q3 25 | 47.7% | — | ||
| Q2 25 | 58.5% | — | ||
| Q1 25 | 55.8% | — | ||
| Q3 24 | 58.5% | — |
| Q3 25 | -156.3% | -314.1% | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -32.8% | — | ||
| Q3 24 | -26.0% | -1145.9% |
| Q3 25 | -177.4% | -303.5% | ||
| Q2 25 | -20.7% | — | ||
| Q1 25 | -32.0% | — | ||
| Q3 24 | -26.8% | -1075.7% |
| Q3 25 | $-0.21 | $-0.26 | ||
| Q2 25 | $-0.04 | — | ||
| Q1 25 | $-0.07 | — | ||
| Q3 24 | $-0.08 | $-0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.8M | $55.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $37.4M | $58.5M |
| Total Assets | $42.7M | $94.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $9.8M | $55.0M | ||
| Q2 25 | $4.0M | — | ||
| Q1 25 | $6.8M | — | ||
| Q3 24 | $9.9M | $153.6M |
| Q3 25 | $37.4M | $58.5M | ||
| Q2 25 | $10.9M | — | ||
| Q1 25 | $11.9M | — | ||
| Q3 24 | $15.8M | $156.4M |
| Q3 25 | $42.7M | $94.8M | ||
| Q2 25 | $16.6M | — | ||
| Q1 25 | $17.3M | — | ||
| Q3 24 | $22.4M | $197.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.5M | $-19.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-3.5M | $-19.1M | ||
| Q2 25 | $-1.8M | — | ||
| Q1 25 | $-2.2M | — | ||
| Q3 24 | — | $-27.3M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $-27.4M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | -912.0% |
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 2.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
